Back to top

Evolus Announces Publication of Independent Study in JAMA Dermatology Demonstrating Jeuveau as a Top Performer Among Leading Neurotoxins | EOLS Stock News

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Evolus, Inc. (EOLS)